Cue Biopharma, Inc. Business Operations Contracts & Agreements
20 Contracts & Agreements
- Collaboration Agreements (14 contracts)
- Indemnification Agreements (1)
- Sales Agreements (4)
- Termination Agreements (1)
- Termination of License Agreement, dated September 9, 2022, between Cue Biopharma, Inc. and MIL 21E, LLC (Filed With SEC on November 14, 2022)
- First Amendment to the Exclusive Patent License and Research Collaboration Agreement with Merck Sharp & Dohme Corp. dated November 9, 2020 (Filed With SEC on March 9, 2021)
- Eighth Amendment to Collaboration, License and Option Agreement, dated December 7, 2020, between the Registrant and LG CHEM LTD (Filed With SEC on March 9, 2021)
- Seventh Amendment to Collaboration, License and Option Agreement, dated May 14, 2020, between the Registrant and LG CHEM LTD (Filed With SEC on March 9, 2021)
- Sixth Amendment to Collaboration, License and Option Agreement, dated February 14, 2020, between the Registrant and LG CHEM LTD (Filed With SEC on March 9, 2021)
- Fifth Amendment to Collaboration, License and Option Agreement, dated January 10, 2020, between the Registrant and LG CHEM LTD (Filed With SEC on March 9, 2021)
- Fourth Amendment to Collaboration, License and Option Agreement, dated December 18, 2019, between the Registrant and LG CHEM LTD (Filed With SEC on March 9, 2021)
- Third Amendment to Collaboration, License and Option Agreement, dated October 29, 2019, between the Registrant and LG CHEM LTD (Filed With SEC on March 9, 2021)
- Second Amendment to Collaboration, License and Option Agreement, dated August 5, 2019, between the Registrant and LG CHEM LTD (Filed With SEC on March 9, 2021)
- First Amendment to Collaboration, License and Option Agreement, dated March 15, 2019, between the Registrant and LG CHEM LTD (Filed With SEC on March 9, 2021)
- At-the-Market Equity Offering Sales Agreement by and between Cue Biopharma, Inc. and Stifel, Nicolaus & Company, Incorporated, dated June 22, 2020 (Filed With SEC on June 22, 2020)
- At-the-Market Equity Offering Sales Agreement by and between Cue Biopharma, Inc. and Stifel, Nicolaus & Company, Incorporated, dated March 27, 2020 (Filed With SEC on March 27, 2020)
- At-the-Market Equity Offering Sales Agreement by and between Cue Biopharma, Inc. and Stifel, Nicolaus & Company, Incorporated, dated November 25, 2019 (Filed With SEC on November 26, 2019)
- At-the-Market Equity Offering Sales Agreement by and between Cue Biopharma, Inc. and Stifel, Nicolaus & Company, Incorporated, dated June 5, 2019 (Filed With SEC on June 5, 2019)
- Collaboration, License and Option Agreement, by and between the Company and LG Chem, Ltd., dated as of November 6, 2018 (Filed With SEC on December 26, 2018)
- Collaboration, License and Option Agreement, by and between the Company and LG Chem, Ltd., dated as of November 6, 2018 (Filed With SEC on November 13, 2018)
- Exclusive Patent License and Research Collaboration Agreement between the Registrant and Merck Sharp & Dohme Corp. dated November 14, 2017 (Filed With SEC on December 13, 2017)
- Exclusive Patent License and Research Collaboration Agreement between the Registrant and Merck Sharp & Dohme Corp. dated November 14, 2017 (Filed With SEC on December 11, 2017)
- Exclusive Patent License and Research Collaboration Agreement between the Registrant and Merck Sharp & Dohme Corp. dated November 14, 2017 (Filed With SEC on December 5, 2017)
- Form of Indemnification Agreement (Filed With SEC on September 21, 2017)
